220 related articles for article (PubMed ID: 29357281)
1. Leflunomide: A promising drug with good antitumor potential.
Zhang C; Chu M
Biochem Biophys Res Commun; 2018 Feb; 496(2):726-730. PubMed ID: 29357281
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action for leflunomide in rheumatoid arthritis.
Fox RI; Herrmann ML; Frangou CG; Wahl GM; Morris RE; Strand V; Kirschbaum BJ
Clin Immunol; 1999 Dec; 93(3):198-208. PubMed ID: 10600330
[TBL] [Abstract][Full Text] [Related]
3. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
4. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
Fragoso YD; Brooks JB
Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Breedveld FC; Dayer JM
Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide: dermatologic perspective.
Sehgal VN; Verma P
J Dermatolog Treat; 2013 Apr; 24(2):89-95. PubMed ID: 21801113
[TBL] [Abstract][Full Text] [Related]
7. Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
Bae J; Park JW
Drug Dev Ind Pharm; 2016; 42(2):254-62. PubMed ID: 26006334
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two molecular scaffolds, 5-methylisoxazole-3-carboxamide and 5-methylisoxazole-4-carboxamide.
Song Y; Zhang Y; Lee AR; Huang WH; Chen B; Palfey B; Shaw J
Curr Pharm Des; 2014; 20(1):146-52. PubMed ID: 23944378
[TBL] [Abstract][Full Text] [Related]
9. Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors.
Furst DE
Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():14-8. PubMed ID: 10646484
[TBL] [Abstract][Full Text] [Related]
10. Chemopreventive effect of leflunomide against Ehrlich's solid tumor grown in mice: Effect on EGF and EGFR expression and tumor proliferation.
Bahr HI; Toraih EA; Mohammed EA; Mohammad HM; Ali EA; Zaitone SA
Life Sci; 2015 Nov; 141():193-201. PubMed ID: 26439991
[TBL] [Abstract][Full Text] [Related]
11. Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Leban J; Vitt D
Arzneimittelforschung; 2011; 61(1):66-72. PubMed ID: 21355448
[TBL] [Abstract][Full Text] [Related]
12. Leflunomide: a drug with a potential beyond rheumatology.
Teschner S; Burst V
Immunotherapy; 2010 Sep; 2(5):637-50. PubMed ID: 20874647
[TBL] [Abstract][Full Text] [Related]
13. [Leflunomide: a new treatment for an old disease].
Monteagudo Sáez I; López Longo FJ; González Fernández CM; Carreño Pérez L
Rev Clin Esp; 2000 May; 200 Monog 1():114-8. PubMed ID: 10901036
[No Abstract] [Full Text] [Related]
14. Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide.
Yamaguchi T; Kakefuda R; Tanimoto A; Watanabe Y; Tajima N
Inflamm Res; 2012 May; 61(5):445-54. PubMed ID: 22245957
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide for the treatment of rheumatoid arthritis.
Olsen NJ; Strand V; Kremer JM
Bull Rheum Dis; 1999; 48(8):1-4. PubMed ID: 10628065
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro.
Jiang L; Zhang W; Li W; Ling C; Jiang M
Toxicol Lett; 2018 Jan; 282():154-165. PubMed ID: 29050931
[TBL] [Abstract][Full Text] [Related]
17. Effects of leflunomide on immune responses and models of inflammation.
Bartlett RR; Anagnostopulos H; Zielinski T; Mattar T; Schleyerbach R
Springer Semin Immunopathol; 1993; 14(4):381-94. PubMed ID: 8322168
[No Abstract] [Full Text] [Related]
18. Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents.
Leger DY; Liagre B; Beneytout JL
Apoptosis; 2006 Oct; 11(10):1747-60. PubMed ID: 16927021
[TBL] [Abstract][Full Text] [Related]
19. [Leflunomide--a new drug for pharmacological immunomodulation].
Wozel G; Pfeiffer C
Hautarzt; 2002 May; 53(5):309-15. PubMed ID: 12063741
[TBL] [Abstract][Full Text] [Related]
20. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice.
Van Roon EN; Jansen TL; Mourad L; Houtman PM; Bruyn GA; Griep EN; Wilffert B; Tobi H; Brouwers JR
Br J Clin Pharmacol; 2004 Jun; 57(6):790-7. PubMed ID: 15151525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
